Welcome to our dedicated page for Thermo Fisher Scientific news (Ticker: TMO), a resource for investors and traders seeking the latest updates and insights on Thermo Fisher Scientific stock.
Thermo Fisher Scientific, Inc. (TMO) is a global leader in providing science-based solutions, offering a wide range of products and services in the life sciences, analytical instruments, specialty diagnostics, and laboratory products sectors. The company's expansive portfolio includes scientific instruments, laboratory equipment, diagnostic consumables, and life science reagents, serving customers both in the United States and internationally.
Thermo Fisher operates through four distinct segments as of end-2023:
- Analytical Technologies (17% of sales): This segment focuses on providing high-quality instruments and software solutions for various scientific applications.
- Specialty Diagnostic Products (10% of sales): This segment specializes in offering diagnostic reagents and instruments for medical and research laboratories.
- Life Science Solutions (23% of sales): This segment provides reagents, instruments, and consumables used in biological research and drug development.
- Lab Products and Services (54% of sales): This is the largest segment, encompassing laboratory supplies, equipment, and contract research organization (CRO) services.
Thermo Fisher is continually expanding its offerings and capabilities through strategic partnerships, acquisitions, and technological innovation. The company's robust financial performance underscores its leadership in the industry, driven by consistent revenue growth, strong market presence, and a commitment to advancing scientific research and healthcare.
Recent achievements include technological advancements in analytical instruments, enhanced diagnostic solutions, and expanded biopharma services, reflecting Thermo Fisher's dedication to supporting life-saving research and diagnostic processes. Thermo Fisher remains committed to delivering high-quality products and services, fostering scientific breakthroughs, and maintaining its position at the forefront of scientific innovation.
Thermo Fisher Scientific (NYSE: TMO) announced the launch of the Applied Biosystems QuantStudio Absolute Q Digital PCR System, the first fully integrated digital PCR system. This innovative technology aims to provide accurate and consistent results in just 90 minutes, enhancing applications in oncology and gene therapy. By acquiring Combinati's advanced dPCR technology, Thermo Fisher aims to expedite innovation in cancer research. The system simplifies workflows, reducing hands-on time to five minutes, minimizing user errors, and accelerating genetic analysis processes for biotech and academic institutions.
Thermo Fisher Scientific (NYSE: TMO) will host a virtual Investor Day on September 17, 2021, from 9:00 a.m. to 11:00 a.m. (EDT). The event will include presentations by senior management, followed by a Q&A session. Investors can access the live webcast through the company's website, with a replay available later. Thermo Fisher Scientific, a leader in serving science, reported annual revenues over $30 billion and employs over 80,000 colleagues to support life sciences research and laboratory productivity.
Thermo Fisher Scientific (NYSE: TMO) has secured a $192.5 million contract from the U.S. Department of Defense to boost domestic production of pipette tips, essential for research and diagnostics, including COVID-19 testing. The award includes co-investment in a new, energy-efficient manufacturing facility in North Carolina, set to commence operations by Q3 2023 and complete by Q3 2024. This initiative aims to enhance supply chain resilience and job creation while supporting the company’s net-zero carbon emissions goal by 2050.
Thermo Fisher Scientific has priced an offering of $3.1 billion in senior notes to finance the pending acquisition of PPD, Inc. The offering includes:
- $700 million of 1.750% senior notes due 2028
- $1.2 billion of 2.000% senior notes due 2031
- $1.2 billion of 2.800% senior notes due 2041
Thermo Fisher Scientific (NYSE: TMO) announced it will offer USD-denominated senior notes to fund part of its acquisition of PPD, Inc. This offering is part of a registration statement filed with the SEC. The company emphasizes that the offering does not constitute an offer to sell or solicit notes in jurisdictions where it would be unlawful. The offering aims to meet capital needs for strategic growth while adhering to market conditions. Thermo Fisher has engaged key financial institutions, including Barclays and Morgan Stanley, as joint book-running managers for this offering.
Thermo Fisher Scientific (NYSE: TMO) has launched a new cGMP plasmid DNA manufacturing facility in Carlsbad, California, addressing the rising demand for plasmid DNA-based therapies and mRNA vaccines. This 67,000-square-foot facility is part of a broader investment strategy aimed at ensuring high-quality materials for gene therapies. The expansion will create over 150 jobs and complements Thermo Fisher's existing infrastructure in various locations. CEO Marc N. Casper emphasized the necessity of this facility for the production of life-saving medicines.
Thermo Fisher Scientific (NYSE:TMO) announced an expansion of its partnership with My Green Lab to enhance sustainability in scientific research. The goal is to obtain the Accountability, Consistency and Transparency (ACT) labeling for its cold temperature storage portfolio by the end of 2021. Over 1,200 additional SKUs are expected to be labeled, thus aiding laboratories in sustainable purchasing. Thermo Fisher offers ENERGY STAR® certified freezers using eco-friendly refrigerants and aims for a 70% reduction in energy consumption compared to conventional alternatives.
Thermo Fisher Scientific (TMO) announced a quarterly cash dividend of $0.26 per common share, payable on October 15, 2021, to shareholders of record as of September 15, 2021. The company continues to showcase its commitment to rewarding shareholders, with annual revenue exceeding $30 billion. Thermo Fisher is recognized for its leadership in laboratory and pharmaceutical services, providing essential support across life sciences and diagnostics sectors.
Thermo Fisher Scientific (NYSE: TMO) will release its Q2 2021 financial results on July 28, 2021, before market opening. A conference call to discuss the results and future expectations will occur at 8:30 a.m. EDT on the same day. Investors can listen via phone or through the company's website. Thermo Fisher, a global leader in scientific services, has an annual revenue exceeding $30 billion and employs over 80,000 individuals worldwide.
FAQ
What is the current stock price of Thermo Fisher Scientific (TMO)?
What is the market cap of Thermo Fisher Scientific (TMO)?
What does Thermo Fisher Scientific, Inc. specialize in?
What are the main segments of Thermo Fisher Scientific?
How much of Thermo Fisher's sales come from Lab Products and Services?
Where does Thermo Fisher Scientific operate?
What recent achievements has Thermo Fisher Scientific made?
What is Thermo Fisher Scientific's stock symbol?
How does Thermo Fisher Scientific support scientific research?
What types of products does Thermo Fisher Scientific offer?
What is Thermo Fisher's commitment to the healthcare industry?
What sets Thermo Fisher Scientific apart in its industry?
